07.28.2026
CHMP Backs Roche’s Susvimo for Wet AMD, European Commission Decision Pending
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Roche’s Susvimo (ranibizumab injection) 100 mg/mL for the treatment of wet age-related macular degeneration (AMD), bringing the therapy one step closer to authorization across the European Union. The recommendation covers use of Susvimo with the Contivue implant, a refillable ocular implant designed to provide continuous delivery of ranibizumab into the vitreous.